

ASX ANNOUNCEMENT

CELLMID REVENUE GUIDANCE UPGRADE

SYDNEY, Thursday, 9 July 2015: Cellmid Limited (ASX: CDY) is pleased to advise that it has upgraded its revenue guidance to \$2M for the financial year ending 30 June 2015. The improved performance is largely the result of increased sales of the Company's consumer health products in Australia and Japan.

During the last quarter of FY2015 Cellmid's consumer health business met the challenge of increasing sales and delivered strong performance accounting for approximately half of the annual revenue. The business is on a solid foundation to continue to grow rapidly. Cellmid is expected to considerably exceed FY2015 sales levels during the upcoming FY2016.

Cellmid will be hosting a conference call to brief the market on its sales and distribution outlook for the Company's consumer health division on Tuesday, 14th July at 12:00pm AEST.

The senior executive team will be providing an update on significant increase in sales and distribution for its evol^{is}® and Advangen® branded hair growth products.

Cellmid CEO, Maria Halasz, will be discussing sales results for FY2015, as well as outlining global plans for the consumer health business for 2016 and beyond. She will provide insights on how sales from the consumer health division increased significantly during 4Q2015, and what that means for future revenue.

Advangen Japan Managing Director, Koichiro Koike, will discuss the Japanese market, in particular the recent increase in direct to customer sales, and will comment on plans for the rest of Asia. He will also report on some of the very important research and development that underpins ongoing success in this highly technical field.

VP of Consumer Health, Evan Rees, will outline the recent expansion of the Australian pharmacy distribution and what the market potential is for the evol^{is}® branded products in our pharmacy, salon and direct to customers channels.

To join the conference call, please dial via the numbers below shortly before the scheduled timeslot. **Conference ID: 191 307** – please provide this ID when joining the call.

Australian participant dial-in numbers:

Local: **+61 2 9007 8048**

Alt. Local: **+61 7 3145 4005**

International participant dial-in numbers:

USA/Canada Toll Free: **1855 624 0077**

UK Toll Free: **0800 051 1453**

Japan Toll Free: **0066 3386 8000**

Hong Kong Toll Free: 800 968 273

Singapore Toll Free: 800 101 2702

For countries not listed, please dial the Australian participant local number listed above. To ask a question during the live Q&A session, participants will need to **press * (star) followed by 1 (*, 1)** on their telephone keypad to enter the Q&A queue.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is a revenue stage Australian biotechnology company with a strong product pipeline. The Company generates revenue through its consumer health business and is also developing innovative novel therapies and diagnostic tests for a number of cancer inflammatory indications. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Advangen Limited

In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 hair growth technologies and products. Since then, Cellmid's FGF5 inhibitor assets have been consolidated in its wholly owned subsidiary, Advangen Limited. Cellmid, under Advangen Limited, has continued innovation and product development in addition to actively building distribution in Australia, China, Japan and other major markets. Since the acquisition of Advangen Inc., Advangen Limited filed a number of new patent applications covering several hair growth agents including midkine, pleiotrophin and a group of novel FGF5 inhibitors.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.